![]() |
市场调查报告书
商品编码
1433469
全球甲状腺消融设备市场 2023-2030Global Thyroid Ablation Devices Market 2023-2030 |
预计全球甲状腺消融设备市场在预测期(2023-2030年)将以9.8%的复合CAGR成长。该市场的成长归因于甲状腺癌盛行率的增加,这创造了对该设备的需求。美国癌症协会估计,2023 年美国甲状腺癌新病例约为 43,720 例(男性 12,540 例,女性 31,180 例)。约 2,120 人死于甲状腺癌(其中男性 970 人,女性 1,150 人)。一个人被诊断出患有甲状腺癌的平均年龄是 51 岁。这种癌症在女性中的发生率约为男性的 3 倍,在白人中的发病率比在黑人中高出约 70%。此外,2022年11月,《老年人口统计:美国老化肖像》一文报道,有5,410万成年人(占美国人口的16.3%)是老年人,其中包括65岁或以上的老年人。预计到2040年老年人口将增至22%,到2060年将增至25%。微创治疗手术需求的不断增长进一步创造了巨大的市场成长空间。
全球甲状腺消融设备市场按类型、产品、应用和最终用途细分。依类型,市场分为射频消融、微波消融等。其中,其他包括影像导引消融。根据产品,市场分为热敏设备和非热敏设备。根据应用,市场分为甲状腺癌和甲状腺结节。此外,根据最终用途,市场细分为医院和诊所、门诊手术中心等。其中,其他包括癌症专科中心。在最终用途中,预计医院和诊所细分市场将在预测期内占据最大的市场份额。该细分市场的大部分份额归功于较低的成本、较高的效率和可用性。
其中,微波消融细分市场预计将在预测期内成长,因为其治疗时间较短、消融区域更宽且散热效应较小。 MWA 系统由发电机、柔性电缆和天线组成。 《腺体外科》发表的一篇文章,题为“甲状腺结节微波消融:经皮治疗的新弓弦?”记录了实验研究和其他器官的研究,MWA可能是甲状腺结节经皮技术的另一个进步,具有减少治疗时间、减少散热效应、创造最适合甲状腺结节形状的椭圆形消融区的优点。
全球甲状腺消融设备市场根据地理位置进一步细分,包括北美(美国和加拿大)、欧洲(英国、义大利、西班牙、德国、法国和欧洲其他地区)、亚太地区(印度、中国、日本、韩国和亚洲其他地区)以及世界其他地区(中东和非洲以及拉丁美洲。其中,亚太地区预计在预测期内将以相当大的CAGR增长。甲状腺消融设备、老年人口的增加、医疗保健支出的增加以及甲状腺癌症发生率的增加推动了亚太地区甲状腺消融设备市场的发展。
预计在预测期内,北美将在甲状腺消融设备市场中占据显着份额。推动北美市场的重要因素包括甲状腺癌盛行率的增加、对微创手术的日益偏好以及技术上可靠的消融手术的可用性。此外,主要参与者正在扩大在该地区的业务,以满足市场上对甲状腺消融设备的需求。 2023年10月,韩国医疗器材公司STARmed Co., Ltd.成立了美国子公司STARmed America。这项策略性倡议凸显了 STARmed 对改善北美患者照护的承诺,这是其更广泛的全球扩张愿景的一部分。 STARmed Co., Ltd. 一直处于热消融创新的前沿,透过微创替代方案为患者提供舒适感。该公司专注于肝臟射频消融 (RFA),并于 2009 年设计了第一个甲状腺专用射频电极。
服务甲状腺消融设备市场的主要公司包括波士顿科学公司、Integra LifeSciences 公司、强生服务公司、美敦力公司等。市场参与者透过各种策略(包括併购、合作、合作、融资和新产品发布),为市场成长做出了巨大贡献,以保持市场竞争力。例如,2023 年 11 月,美国食品药物管理局 (FDA) 批准贝尔德医疗的微波消融 (MWA) 系统和一次性针头在美国使用。这项许可证是透过 Baird Medical 子公司 Betters Medical 获得的,这意味着美国的医生现在可以使用该技术来消融甲状腺结节、乳房肿瘤和其他需要切除软组织的疾病。 2023年7月,中国国家药品监督管理局(NMPA)批准该系统用于治疗良性甲状腺结节。
Global Thyroid Ablation Devices Market Size, Share & Trends Analysis Report by Type (Radiofrequency Ablation, Microwave Ablation, and Others), by Product (Thermal-based Devices and Non-thermal-based Devices), By Application, (Thyroid Cancer and Thyroid Nodules), by End-use (Hospitals and Clinics, Ambulatory Surgical Centers, and Others), Forecast Period (2023-2030)
The global thyroid ablation devices market is anticipated to grow at a considerable CAGR of 9.8% during the forecast period (2023-2030). The growth of this market is attributed to the increasing prevalence of thyroid cancer which has created demand for this device. In 2023, the American Cancer Society estimated thyroid cancer in the US, about 43,720 new cases of thyroid cancer (12,540 in men and 31,180 in women). About 2,120 deaths from thyroid cancer (970 in men and 1,150 in women). The average age when a person is diagnosed with thyroid cancer is 51. This cancer is about 3 times more common in women than in men, and it is about 70% more common in white people than in black people. In addition, in November 2022, the article "Senior Population Statistics: A Portrait of Aging Americans", reported 54.1 million adults or 16.3% of the US population are seniors including aged 65 or older. The senior population is expected to rise to 22% by 2040 and 25% by 2060. The growing demand for minimally invasive treatment surgeries has further created huge scope for the market growth.
The global thyroid ablation devices market is segmented by type, product, application and end-use. Based on the type, the market is sub-segmented into radiofrequency ablation, microwave ablation, and others. Where, others include image-guided ablation. Based on the product, the market is sub-segmented into thermal-based devices, and non-thermal-based devices. Based on the application, the market is sub-segmented into thyroid cancer, and thyroid nodules. Further, based on end-use, the market is sub-segmented into hospitals and clinics, ambulatory surgical centers, and others. Where, other include cancer specialty centers. Among the end-use, the hospitals and clinics sub-segment is anticipated to hold the largest market share during the forecast period. The large share of this segment is credited to the lower costs, higher efficiency, and availability.
Among the type, microwave ablation sub-segments expected to grow over the forecast period, owing to the owing to shorter treatment duration, a broader ablation zone, and less heat sink effect. A generator, a flexible cable, and an antenna make up the MWA system. An article published by Gland Surgery, namely "Microwave ablation for thyroid nodules: a new string to the bow for percutaneous treatments?" recorded experimental studies and studies on other organs, MWA could be a further step in percutaneous techniques for thyroid nodules, giving the advantage to reduce treatment time, reduce the heat sink effect, create an ellipsoidal ablated zone which best fits with the shaping of thyroid nodules.
The global thyroid ablation devices market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East &Africa, and Latin America. Among these, Asia-Pacific is anticipated to grow at a considerable CAGR over the forecast period. The growing demand for thyroid ablation devices, increasing geriatric population, the rising healthcare expenditure, and increasing incidences of thyroid cancer cases driving the thyroid ablation devices market in the Asia-Pacific.
North America is expected to hold a prominent share in the thyroid ablation devices market during the forecast period. The significant factors fueling the North America market include increasing prevalence of thyroid cancer, growing preference for minimally invasive surgeries and availability of technically sound ablation procedures. Further, the key players are expanding their presence into the region to cater to the demand for thyroid ablation devices in the market. In October 2023,STARmed Co., Ltd., a South Korean medical device company, launched its US subsidiary, STARmed America. This strategic move underscores STARmed's commitment to improving patient care in North America as part of its broader vision for global expansion. STARmed Co., Ltd. has been at the forefront of thermal ablation innovations, offering patient comfort through minimally invasive alternatives. The company focuses on Liver Radiofrequency Ablation (RFA), Radiofrequency Ablation (RFA), and engineered the first thyroid-specific RF electrodes in 2009.
The major companies serving the thyroid ablation devices market include Boston Scientific Corp., Integra LifeSciences Corp., Johnson & Johnson Services, Inc., Medtronic Plc, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in November 2023, the US Food and Drug Administration (FDA) cleared Baird Medical's microwave ablation (MWA) system and disposable needles for use in the US. The clearance, which is through Baird Medical subsidiary Betters Medical, means doctors in the US can now use the technology to ablate thyroid nodules, breast tumors and other diseases where soft tissue needs to be removed. In July 2023, China's National Medical Products Administration (NMPA) approved the system to treat benign thyroid nodules.